Seeking Alpha

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...
MedPage Today

Humira Clobbers Biosimilars in Battle for Part D Coverage

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...
Healio

US Veterans Affairs to replace Humira with biosimilar on national formulary

Please provide your email address to receive an email when new articles are posted on . Hadlima was approved as a biosimilar to Humira in 2019. The drug is available in a pre-filled syringe or a ...
Monthly Prescribing Reference

FDA Designates Yuflyma an Interchangeable Biosimilar to Humira

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
Seeking Alpha

AbbVie faces interchangeable Humira biosimilar at 81% discount

German drugmaker Boehringer Ingelheim announced Monday that it launched an interchangeable biosimilar to AbbVie’s (NYSE:ABBV) blockbuster arthritis therapy Humira at an 81% discount to the reference ...